Authors
Latest:
Dr Brunner on the Role of the Dermatologist in BPDCN Diagnosis and TreatmentPatrick M. Brunner, MD, discusses how collaboration between dermatologists and oncologists is critical for both accurate diagnosis and the selection of effective treatment approaches for patients with blastic plasmacytoid dendritic cell neoplasm.
Latest:
Examining LIFU–Aided Liquid Biopsy in Glioblastoma: Excitement Surrounding Focused Ultrasound WavesIn this last episode of OncChats: Examining LIFU–Aided Liquid Biopsy in Glioblastoma, Manmeet Singh Ahluwalia, MD, MBA, FASCO, and Michael W. McDermott, MD, shed light on the excitement surrounding the use of low-intensity focused ultrasound in cancer and other conditions.
Latest:
Dr O’Brien on Tucatinib Plus Trastuzumab/Capecitabine for Leptomeningeal Metastases in HER2+ Breast CancerBarbara Jane O’Brien, MD, discusses tucatinib plus trastuzumab and capecitabine for leptomeningeal metastases in HER2-positive breast cancer.
Latest:
Future Directions in the Treatment of Recurrent or Metastatic Cervical CancerThe panel closes their discussion by highlighting challenges in the treatment of cervical cancer, emphasizing the need for more focus on clinical trials and therapies, as well as addressing disparities in cancer care, particularly for patients of color.
Latest:
Immunotherapeutics Aim for Larger Role in Prostate CancerHighly effective tools, such as immunotherapeutic agents, have emerged for the treatment of patients with a wide range of malignancies.
Latest:
Dr. Visco on Results from the MANTLE-FIRST Study in Relapsed/Refractory MCLCarlo Visco, MD, discusses the results of early relapse versus late relapse in the MANTLE-FIRST study with ibrutinib versus chemoimmunotherapy in mantle cell lymphoma.
Latest:
Rapid Readouts: Final Results From the Phase 3 PROTECTIVE-2 TrialDouglas W. Blayney, MD, presents data from the 2021 American Society of Clinical Oncology Annual Meeting on the final results from the phase 3 PROTECTIVE-2 trial of Plinabulin and Pegfilgrastim in breast cancer patients treated with high febrile neutropenia risk chemotherapy.
Latest:
Diffuse Large B-Cell Lymphoma: Unmet Needs and Future Directions in CareClosing out their discussion on the management of relapsed/refractory diffuse large B-cell lymphoma, expert panelists highlight unmet needs and share excitement for future evolutions in the treatment landscape.
Latest:
Dr. Winestone on Disparities with Diagnosis in Pediatric LeukemiaLena Winestone, MD, discusses disparities with diagnosis in pediatric leukemia.
Latest:
Dr Deek on the Investigation of Immune Cell Infiltration in MIBCMatthew Pierre Deek, MD, discusses the significance of pretreatment immune cell infiltration in patients with muscle-invasive bladder cancer who had been treated with definitive chemoradiation.
Latest:
Dr Lazzaro on Lung Cancer Screening in High-Risk IndividualsRichard Lazzaro, MD, FACS, discusses the advantages of standard low-dose computed tomography scans in lung cancer screening in high-risk individuals, as well as future opportunities to integrate biomarker-based assays into screening protocols to improve early detection.
Latest:
Emerging Treatments for MyelofibrosisAndrew Kuykendall, MD, and Raajit K. Rampal, MD, PhD, conclude that the increasing complexity in myelofibrosis treatment options, including multiple JAK inhibitors and emerging combination therapies, signals an exciting era of individualized care, yet underscores the need for reevaluating study end points to enhance patient outcomes further.
Latest:
Building the Optimal Patient Experience Takes Planning and EffortEnsuring a positive patient experience should be a top priority throughout the entire treatment journey, as higher patient satisfaction can drive improved health outcomes, treatment adherence, and quality of life.
Latest:
Cancer Researchers and Student Athletes Are “Here to Win” for Innovation, Discovery, and HopeBuilding an innovative cancer research project takes time, creativity, and most importantly, a team of scientists working together on why a new way to treat cancer or keep the cancer from spreading to other parts of the body.
Latest:
Dr Bagegni on the Prevalence of ILD With Trastuzumab Deruxtecan in HER2+ Breast CancerNusayba Bagegni, MD, discusses the prevalence of interstitial lung disease in patients with HER2-positive breast cancer treated with trastuzumab deruxtecan.
Latest:
Dr. Meyerhardt on the Rationale for the CALGB/SWOG 80702 Trial in Colon CancerJeffrey A. Meyerhardt, MD, MPH, FASCO, discusses the rationale for the randomized phase 3 CALGB/SWOG 80702 trial in colon cancer.
Latest:
SUNLIGHT QOL Data Show Positive Outcomes With Trifluridine-Tipiracil Plus Bevacizumab in CRC : With Joleen Hubbard, MDDr Hubbard discusses efficacy, safety, and quality of life outcomes from the SUNLIGHT trial of trifluridine-tipiracil plus bevacizumab in metastatic CRC.
Latest:
Dr Backhus on Defining Borderline-Resectable Lung CancerLeah Backhus, MD, MPH, FACS, discusses the evolving definition of borderline resectable lung cancer.
Latest:
Dr Hecht on Barriers to Enrollment into the BASECAMP-1 Study in Solid TumorsJ. Randolph (Randy) Hecht, MD, discusses barriers to enrollment in the observational BASECAMP-1 study and the phase 1/2 EVEREST-1 study, which will investigate HLA-A*02 as a target for the novel CAR T-cell therapy A2B530 in patients with solid tumors.
Latest:
Dr. Schweizer on the Results of the HERO Trial in Prostate CancerMichael Schweizer, MD, discusses the results of the HERO trial in prostate cancer.
Latest:
Dr Ikegawa on An Analysis of Rapidly Manufactured Durcabtagene Autoleucel in R/R Multiple MyelomaShuntaro Ikegawa, MD, PhD, discusses results from a correlative analysis of an ongoing phase 1 trial evaluating the use of a novel T-Charge rapid manufacturing platform for the production of durcabtagene autoleucel CAR T-cells in multiple myeloma.
Latest:
Dr Piulats on Validating Predictive Biomarkers for Talazoparib Plus Enzalutamide in mCRPCJosep Maria Piulats Rodriguez, MD, PhD, discusses next steps for validating predictive biomarkers of efficacy to treatment with talazoparib plus enzalutamide in mCRPC.
Latest:
Dr Khan on the Effects of Financial Toxicity on Survival Outcomes in Patients With CancerHiba Khan, MD, MPH, discusses how adverse financial events may contribute to the risk of early mortality in patients with cancer.
Latest:
Biomarkers Help Predict the Role of Chemotherapy in Biologic AgingStimuli for biologic aging include ionizing radiation, ultraviolet light, diet, exercise, oxidative stresses, and perhaps, worst of all, smoking. All of these can trigger intracellular processes, including DNA methylation, or epigenetic change, telomere shortening and damage, DNA damage, and mitochondrial dysfunction.
Latest:
Dr Leidner on the DPV-001 Vaccine Plus PD-1 Inhibition in Metastatic HNSCCRom S. Leidner, MD, discusses the rationale for studying DPV-001 plus PD-1 inhibition in advanced or metastatic head and neck squamous cell carcinoma.
Latest:
Strategies to Improve CAR T-cell Durability in LymphomaSamuel Yamshon, MD, of Weill Cornell Medicine/NewYork-Presbyterian, discusses strategies to improve CAR T-cell durability in patients with non-Hodgkin lymphoma.
Latest:
Delivering Long-Term Results for Blood Cancer PatientsWhile great progress has been made in developing and delivering new treatment options for chronic lymphocytic leukemia, recognizing the chronic nature of the disease and being cognizant of side effects that can have a major impact on a patient’s quality of life remains an important responsibility.
Latest:
Benefit of Elacestrant Improves With Longer Duration of CDK4/6 Inhibition in Patients With ER+/HER2– Metastatic Breast CancerTreatment with the oral selective estrogen receptor degrader elacestrant following treatment with CDK4/6 inhibitors improved progression-free survival outcomes vs standard care options in patients with estrogen receptor-positive, HER2-negative metastatic breast cancer.
Latest:
Dr. Roland on Findings From a Phase 2 Study With Neoadjuvant Checkpoint Blockade in SarcomaChristina L. Roland, MD, MS, FACS, discusses the results from a phase 2 study evaluating neoadjuvant checkpoint blockade study in patients with undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.
